Manufacturer of Controlled Substances; Notice of Application; Cayman Chemical Company, 1889-1890 [2014-00200]

Download as PDF 1889 Federal Register / Vol. 79, No. 7 / Friday, January 10, 2014 / Notices Drug Schedule Amphetamine (1100) .................... Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Pentobarbital (2270) ..................... Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Levorphanol (9220) ...................... Morphine (9300) ........................... Oxymorphone (9652) ................... Remifentanil (9739) ...................... Fentanyl (9801) ............................ II II II II II II II II II II II II Drug The company plans to import the listed controlled substances in finished dosage form (FDF) from foreign sources for analytical testing and clinical trials in which the foreign FDF will be compared to the company’s own domestically-manufactured FDF. This analysis is required to allow the company to export domesticallymanufactured FDF to foreign markets. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Mylan Pharmaceuticals, Inc., to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Mylan Pharmaceuticals, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: December 31, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2014–00206 Filed 1–9–14; 8:45 am] Schedule Methyphendiate (1724) ................ Levorphanol (9220) ...................... Noroxymorphone (9668) .............. Tapentadol (9780) ........................ II II II II The company plans to import the listed controlled substances for clinical trials, analytical research and testing. The import of the above listed basic classes of controlled substances will be granted only for analytical testing and clinical trials. This authorization does not extend to the import of a finished FDA approved or non-approved dosage form for commercial distribution in the United States. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Fisher Clinical Services, Inc., to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Fisher Clinical Services, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: December 31, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE mstockstill on DSK4VPTVN1PROD with NOTICES on September 25, 2013, 78 FR 59064, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances: Drug Enforcement Administration [FR Doc. 2014–00179 Filed 1–9–14; 8:45 am] Importer of Controlled Substances; Notice of Registration; Fisher Clinical Services, Inc. BILLING CODE 4410–09–P By Notice dated September 16, 2013, and published in the Federal Register VerDate Mar<15>2010 16:40 Jan 09, 2014 Jkt 232001 PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Cayman Chemical Company Pursuant to 21 CFR 1301.33(a), this is notice that on June 27, 2013, Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Cathinone (1235) .......................... Methcathinone (1237) .................. 4-Methyl-N-methylcathinone (1248). N-Ethylamphetamine (1475) ........ N,N-Dimethylamphetamine (1480) Aminorex (1585) ........................... 4-Methylaminorex (cis isomer) (1590). Gamma Hydroxybutyric Acid (2010). JWH–250 (6250) .......................... SR–18 also known as RCS–8 (7008). XLR11 (7011) ............................... JWH–019 (7019) .......................... AKB48 (7048) ............................... JWH–081 (7081) .......................... SR–19 also known as RCS–4 (7104). 1-Pentyl-3-(1-naphthoyl)indole (7118). JWH–122 (7122) .......................... UR–144 (7144) ............................. 1-Butyl-3-(1-naphthoyl)indole (7173). 1-[2-(4-Morpholinyl)ethyl]-3- ......... (1-naphthoyl) indole (7200) .......... AM–2201 (7201) ........................... JWH–203 (7203) .......................... Alpha-ethyltryptamine (7249) ....... 5-(1,1-Dimethylheptyl)-2-[(1R,3S)3-hydroxycyclohexyl]-phenol (7297). 5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl]-phenol (7298). Lysergic acid diethylamide (7315) 2,5-Dimethoxy-4-(n)propylthiophenethylamine (7348). Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 2C–T–2 (7385) ............................. 3,4,5-Trimethoxyamphetamine (7390). 4-Bromo-2,5dimethoxyamphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 4-Methyl-2,5dimethoxyamphetamine (7395). E:\FR\FM\10JAN1.SGM 10JAN1 Schedule I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1890 Federal Register / Vol. 79, No. 7 / Friday, January 10, 2014 / Notices mstockstill on DSK4VPTVN1PROD with NOTICES Drug Schedule 2,5-Dimethoxyamphetamine (7396). JWH–398 (7398) .......................... 2,5-Dimethoxy-4ethylamphetamine (7399). 3,4-Methylenedioxyamphetamine (7400). 5-Methoxy-3,4methylenedioxyamphetamine (7401). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (7405). 4-Methoxyamphetamine (7411) ... 5-Methoxy-N-Ndimethyltryptamine (7431). Alpha-methyltryptamine (7432) .... Bufotenine (7433) ......................... Diethyltryptamine (7434) .............. Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... Psilocyn (7438) ............................. 5-Methoxy-N,Ndiisopropyltryptamine (7439). N-Ethyl-1-phenylcyclohexylamine (7455). N-Benzylpiperazine (7493) ........... 2C–D (7508) ................................. 2C–E (7509) ................................. 2C–H (7517) ................................. 2C–I (7518) .................................. 2C–C (7519) ................................. 2C–N (7521) ................................. 2C–P (7524) ................................. 2C–T–4 (7532) ............................. MDPV (7535) ................................ Methylone (7540) ......................... AM–694 (7694) ............................. Desmorphine (9055) ..................... Dihydromorphine (9145) ............... Heroin (9200) ............................... Morphine-N-oxide (9307) ............. Normorphine (9313) ..................... Tilidine (9750) ............................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Lisdexamfetamine (1205) ............. Pentobarbital (2270) ..................... Phencyclidine (7471) .................... Phenylacetone (8501) .................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Levomethorphan (9210) ............... Meperidine (9230) ........................ Meperidine intermediate-B (9233) Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ VerDate Mar<15>2010 16:40 Jan 09, 2014 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II II II II II II II II II II II II II II Jkt 232001 The company plans to manufacture reference standards for distribution to their research and forensics customers. In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic tetrahydrocannabinol (7370). No other activity for this drug code is authorized for this registration. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 11, 2014. Dated: December 31, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2014–00200 Filed 1–9–14; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Meperidine (9230) ........................ Methadone (9250) ........................ Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Tapentadol (9780) ........................ Fentanyl (9801) ............................ Schedule II II II II II II II II II II II II The company plans on manufacturing the listed controlled substances in bulk for sale to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 11, 2014. Dated: December 31, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2014–00204 Filed 1–9–14; 8:45 am] Drug Enforcement Administration BILLING CODE 4410–09–P Manufacturer of Controlled Substances Notice of Application Cody Laboratories, Inc. DEPARTMENT OF JUSTICE Pursuant to 21 CFR 1301.33(a), this is notice that on June 12, 2013, Cody Laboratories, Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule Dihydromorphine (9145) ............... Amphetamine (1100) .................... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... 4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333). Phenylacetone (8501) .................. Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Diphenoxylate (9170) ................... PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 I II II II II II II II II II II II II II II Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; Organix, Inc. By Notice dated August 20, 2013, and published in the Federal Register on August 26, 2013, 78 FR 52801, Organix, Inc., 240 Salem Street, Woburn, Massachusetts 01801, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Psilocybin (7437) .......................... Psilocyn (7438) ............................. Schedule I I I I The company plans to synthesize small quantities of the listed controlled substances to make reference standards which will be distributed to their customers. E:\FR\FM\10JAN1.SGM 10JAN1

Agencies

[Federal Register Volume 79, Number 7 (Friday, January 10, 2014)]
[Notices]
[Pages 1889-1890]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-00200]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; 
Cayman Chemical Company

    Pursuant to 21 CFR 1301.33(a), this is notice that on June 27, 
2013, Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor, 
Michigan 48108, made application by renewal to the Drug Enforcement 
Administration (DEA) to be registered as a bulk manufacturer of the 
following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
4-Methyl-N-methylcathinone (1248)..........  I
N-Ethylamphetamine (1475)..................  I
N,N-Dimethylamphetamine (1480).............  I
Aminorex (1585)............................  I
4-Methylaminorex (cis isomer) (1590).......  I
Gamma Hydroxybutyric Acid (2010)...........  I
JWH-250 (6250).............................  I
SR-18 also known as RCS-8 (7008)...........  I
XLR11 (7011)...............................  I
JWH-019 (7019).............................  I
AKB48 (7048)...............................  I
JWH-081 (7081).............................  I
SR-19 also known as RCS-4 (7104)...........  I
1-Pentyl-3-(1-naphthoyl)indole (7118)......  I
JWH-122 (7122).............................  I
UR-144 (7144)..............................  I
1-Butyl-3-(1-naphthoyl)indole (7173).......  I
1-[2-(4-Morpholinyl)ethyl]-3-..............  I
(1-naphthoyl) indole (7200)................
AM-2201 (7201).............................  I
JWH-203 (7203).............................  I
Alpha-ethyltryptamine (7249)...............  I
5-(1,1-Dimethylheptyl)-2-[(1R,3S)- 3-        I
 hydroxycyclohexyl]-phenol (7297).
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-          I
 hydroxycyclohexyl]-phenol (7298).
Lysergic acid diethylamide (7315)..........  I
2,5-Dimethoxy-4-(n)-                         I
 propylthiophenethylamine (7348).
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
2C-T-2 (7385)..............................  I
3,4,5-Trimethoxyamphetamine (7390).........  I
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I

[[Page 1890]]

 
2,5-Dimethoxyamphetamine (7396)............  I
JWH-398 (7398).............................  I
2,5-Dimethoxy-4-ethylamphetamine (7399)....  I
3,4-Methylenedioxyamphetamine (7400).......  I
5-Methoxy-3,4-methylenedioxyamphetamine      I
 (7401).
N-Hydroxy-3,4-methylenedioxyamphetamine      I
 (7402).
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
4-Methoxyamphetamine (7411)................  I
5-Methoxy-N-N-dimethyltryptamine (7431)....  I
Alpha-methyltryptamine (7432)..............  I
Bufotenine (7433)..........................  I
Diethyltryptamine (7434)...................  I
Dimethyltryptamine (7435)..................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
5-Methoxy-N,N-diisopropyltryptamine (7439).  I
N-Ethyl-1-phenylcyclohexylamine (7455).....  I
N-Benzylpiperazine (7493)..................  I
2C-D (7508)................................  I
2C-E (7509)................................  I
2C-H (7517)................................  I
2C-I (7518)................................  I
2C-C (7519)................................  I
2C-N (7521)................................  I
2C-P (7524)................................  I
2C-T-4 (7532)..............................  I
MDPV (7535)................................  I
Methylone (7540)...........................  I
AM-694 (7694)..............................  I
Desmorphine (9055).........................  I
Dihydromorphine (9145).....................  I
Heroin (9200)..............................  I
Morphine-N-oxide (9307)....................  I
Normorphine (9313).........................  I
Tilidine (9750)............................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Lisdexamfetamine (1205)....................  II
Pentobarbital (2270).......................  II
Phencyclidine (7471).......................  II
Phenylacetone (8501).......................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Levomethorphan (9210)......................  II
Meperidine (9230)..........................  II
Meperidine intermediate-B (9233)...........  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Thebaine (9333)............................  II
Oxymorphone (9652).........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture reference standards for 
distribution to their research and forensics customers.
    In reference to drug code 7360 (Marihuana), the company plans to 
bulk manufacture cannabidiol as a synthetic intermediate. This 
controlled substance will be further synthesized to bulk manufacture a 
synthetic tetrahydrocannabinol (7370). No other activity for this drug 
code is authorized for this registration.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODW), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than March 11, 2014.

    Dated: December 31, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2014-00200 Filed 1-9-14; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.